Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry.

[1]  A. Go,et al.  Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. , 2015, Journal of the American College of Cardiology.

[2]  Jeroen J. Bax,et al.  The universal definition of myocardial infarction , 2015, Oxford Medicine Online.

[3]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[4]  E. Vicaut,et al.  Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.

[5]  R. Mehran,et al.  Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. , 2014, European heart journal.

[6]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[7]  A. Zwinderman,et al.  Timing of Mortality After Severe Bleeding and Recurrent Myocardial Infarction in Patients With ST-Segment–Elevation Myocardial Infarction , 2013, Circulation. Cardiovascular interventions.

[8]  David J Cohen,et al.  Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. , 2013, JAMA.

[9]  Sunil V. Rao,et al.  Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. , 2012, JACC: Cardiovascular Interventions.

[10]  M. Hadamitzky,et al.  Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention , 2012, Circulation.

[11]  Deepak L. Bhatt,et al.  Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. , 2011, American heart journal.

[12]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[13]  Seung‐Jung Park,et al.  Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. , 2011, JACC. Cardiovascular interventions.

[14]  R. Giugliano,et al.  Prior aspirin use and outcomes in acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[15]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[16]  M. Pencina,et al.  Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. , 2009, JACC. Cardiovascular interventions.

[17]  J. Ware,et al.  Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.

[18]  M. Zwahlen,et al.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. , 2008, Journal of the American College of Cardiology.

[19]  S. Yusuf,et al.  Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. , 2008, European heart journal.

[20]  A. Kastrati,et al.  Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.

[21]  E. Topol,et al.  Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. , 2007, The American journal of cardiology.

[22]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[23]  H. White,et al.  Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.

[24]  D. Simon,et al.  Aspirin resistance or variable response or both? , 2006, The American journal of cardiology.

[25]  C. Meisinger,et al.  Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. , 2006, European heart journal.

[26]  Michal Abrahamowicz,et al.  A proportional hazards model with time-dependent covariates and time-varying effects for analysis of fetal and infant death. , 2004, American journal of epidemiology.

[27]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[28]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[29]  G. Stone,et al.  Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Substudy). , 2014, The American journal of cardiology.

[30]  C. Fang.  Duration of dual antiplatelet therapy after implantation of drug-eluting stents , 2012 .